Share this page: More

Kelly E. Dooley

Kelly E. Dooley

Department Affiliation: Primary: Medicine, Divisions of Clinical Pharmacology and Infectious Diseases; Secondary:  Pharmacology and Molecular Sciences
Degree: M.D., Duke University; Ph.D., Johns Hopkins Bloomberg School of Public Health
Rank: Associate Professor
Telephone Number: 410-287-0517
Fax Number: 410-614-9978
E-mail address:
School of Medicine Address: Osler 508, 600 N. Wolfe Street, Baltimore, MD 21287

Clinical pharmacology of anti-infective agents; Evaluation of new drug regimens for the treatment of tuberculosis and co-treatment of TB and HIV

Research focuses on clinical pharmacology of new anti-tuberculosis regimens with an emphasis on: (1) Phase I clinical trials of new or existing anti-TB drugs including dose escalation trials and studies of drug-drug interactions between anti-TB agents and antiretrovirals to treat HIV; (2) Use of PK/PD analysis and modelling in Phase II tuberculosis clinical treatment trials to determine concentration-effect relationships that will allow for optimization of dosing; and (3) Evaluation of TB and HIV drug concentrations in special populations, such as pregnant women and children; (4) Evaluation of treatment-shortening regimens for drug-sensitive TB and investigational regimens for treatment of multidrug-resistant TB; and (5) Translational work involving novel animal models of cavitary pulmonary TB disease to understand drug distribution in diseased lung.

Representative Publications:

  • Svensson, E.M., Aweeka, F., Park, J.-G., Marzan, F., Dooley, K.E.*, Karlsson, M.O.* (authors contributed equally). Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients co-infected with HIV and tuberculosis.  Antimicrobial Agents and Chemotherapy 57(6): 2780-2787, 2013.  Pub Med Reference
  • Dooley, K.E., Sayre, P., Borland, J., Purdy, E., Chen, S., Song, I., Peppercorn, A., Everts, S., Piscitelli, S. Safety, tolerability and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin; results of a phase 1 study among healthy subjects. Journal of AIDS 62:21-27, 2013. Pub Med Reference
  • Dooley, K.E., Obuku, E.A., Durakovic, N., Belitsky, V., Mitnick, C., Nuermberger, E.L.; on behalf of the Efficacy Subgroup, RESIST-TB. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untappted potential? Journal of Infectious Diseases 207(9): 1352-1358, 2013.  Pub Med Reference
  • Dooley, K.E., Kim, P.S., Williams, S.D., Hafner, R.  TB and HIV therapeutics: Pharmacology research priorities. AIDS Research and Treatment 2012, Epub Jul 5. Pub Med Reference
  • Kizub, D., Ghali, I., Sabouni, R., Bourkadi, J.E., Bennani, K., El Aouad, R., Dooley, K.E. Qualitative study of perceived causes of tuberculosis treatment default among health care workers in Morocco. International Journal of Tuberculosis and Lung Disease 16(9): 1214-20, 2012. Pub Med Reference
  • Dooley, K.E., Mitnick, C., DeGroote, M.A., Obuku, E., Belitsky, V., Hamilton, C.D., Makhene, M., Shah, S., Brust, J.C.M., Durakovic, N., Nuermberger, E.; on behalf of the Efficacy Subgroup, RESIST-TB. Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis. Clinical Infectious Diseases 55: 572-581, 2012. Pub Med Reference
  • Dooley, K.E., Bliven-Sizemore, E.E., Weiner, M., Lu, Y., Nuermberger, E.L., Hubbard, W.C., Fuchs, E.J., Melia, M., Burman, W.J., and Dorman, S.E. Safety and pharmacokinetics of escalating daily doses of rifapentine, an anti-tuberculosis drug, in healthy volunteers. Clinical Pharmacology and Therapeutics 91: 881-888, 2012. Pub Med Reference
  • Dooley, K.E., Park, J.G., Swindells, S., Allen, R., Haas, D.W., Cramer, Y., Aweeka, F., Wiggins, I., Gupta, A., Lizak, P., Qasba, S., van Heeswijk, R., Flexner, C., the ACTG 5267 Study Team. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group study A5267. JAIDS 59: 455-462, 2012. Pub Med Reference
  • Burman, W., Dooley, K.E., Nuermberger, E. The rifamycins: renewed interest in an old drug class.  In Progress in Respiratory Research, Volume 40, Chapter title: "Antituberculosis Chemotherapy", edited by Peter Donald and Paul van Helden, Karger AG - Medical and Scientific Publishers
  • Almeida, D., Converse, P.J., Ahmad, Z., Dooley, K.E., Nuermberger, E.L., Grosset, J. Activities of rifampin, rifapentine and clarithromycin, alone and in combination, against Mycobacterium ulcerans disease in mice. PLoS Neglected Tropical Diseases, 5: e933, 2011.  Pub Med Reference
  • Matteelli, A., Carvalho, A.C.C., Dooley, K.E., and Kritski, A.  TMC207: the first compound of a new class of potent antituberculosis drugs. Future Medicine, 5: 849-58, 2010.  Pub Med Reference
  • Dooley, K.E. and Chaisson, R.E.  Tuberculosis and Diabetes Mellitus: The Convergence of Two Epidemics.   Lancet Infectious Diseases 9: 737-746, 2009.  Pub Med Reference
  • Dooley, K.E., Tang, T., Golub, J., Dorman, S.E., and Cronin, W. Imparct of Diabetes Mellitus on Treatment Outcomes of Patients with Active Tuberculosis. American Journal of Tropical Medicine and Hygiene 80: 634-9, 2009. Pub Med Reference
  • Dooley, K.E., Flexner, C., and Andrade, A.S.  Drug Interactions Involving Combination Antiretroviral Therapy and Other Anti-Infective Agents: Repercussions for Resource-Limited Countries.  Journal of Infectious Diseases 198: 948-61, 2008.  Pub Med Reference

Other graduate programs in which Dr. Dooley participates: None